Mr. Richard Paulson has been the Chief Executive Officer, President and Director of the company since 2021. Prior to this, he served as Executive Vice President of Ipsen Pharmaceuticals Inc and Chief Executive Officer of Ipsen North America from February 2018 to May 2021. Mr. Paulson also worked at Amgen for 10 years holding varying leadership positions across Europe and North America, including Vice President and General Manager of Amgen's U.S. Oncology Business Unit and Vice President of Marketing for Amgen's U.S. Oncology Business, General Manager of Amgen Germany, and General Manager of Amgen Central & Eastern Europe. Prior to Amgen, Mr. Paulson held a number of global leadership positions at Pfizer Inc., including serving as General Manager of Pfizer South Africa and Pfizer Czech Republic. Mr. Paulson also previously held a variety of sales, marketing, and market access roles with increasing seniority at GlaxoWellcome in Canada.

Mr. Michael P. Mason has been the Chief Financial Officer, the Executive Vice President and the Treasurer of the company since 2021. Prior to this, he served as the Vice President of Finance and Treasurer of Alnylam Pharmaceuticals, Inc from 2011 until 2019, Principal Accounting Officer from 2011 to 2018, and as its Principal Financial Officer from 2011 to 2016. From 2005 to 2011, he served as Alnylam’s Corporate Controller, from 2000 through 2005, Mr. Mason held several finance and commercial roles at Praecis Pharmaceuticals Inc, including Corporate Controller. Prior to Praecis, he worked in the audit practice at KPMG LLP.

Mr. James Accumanno has been the Chief Compliance Officer of the company since 2022. Prior to this, he served in Executive Director of Legal and Compliance from 2021. Mr. Accumanno also served as the Head of commercial legal team at AMAG and in the legal and compliance team at Novo Nordisk and Bayer Healthcare Pharmaceuticals.

Dr. Reshma Rangwala has been the Executive Vice President and Chief Medical Officer of the company since 2022. Prior to this, she served as the Chief Medical Officer at Aravive. Dr. Rangwala also served as Vice President of Medical at Genmab from 2017 to 2020 and Executive Clinical Director at Merck & Co from 2012 to 2017.

Ms. Sohanya Cheng has been Executive Vice President and Chief Commercial Officer of the company since 2021. Prior to this, she served as the Vice President of Sales and Commercial. Ms. Cheng also served as the Vice President, Head of Marketing, at Arrowhead Pharmaceuticals, Inc from August 2020 to December 2020. He also served as the Executive Director, Head of National Sales Force & Oncology Contracting Strategy from October 2019 to August 2020, Executive Director, Head of Marketing & Sales for multiple myeloma business from June 2018 to October 2019; and Chief of Staff to General Manager and Strategy & Operations Director for its oncology business from June 2017 to June 2018 at Amgen.